Skip to search formSkip to main contentSkip to account menu

Cytarabine liposome

Known as: Encapsulated Cytarabine, Liposomal Cytarabine, cytarabine (liposomal) 
A form of the anticancer drug cytarabine that is contained inside very tiny, fat-like particles. It may have fewer side effects and work better than… 
National Institutes of Health

Related topics

Related topics

10 relations
CytarabineCytarabine liposome InjectionDrug AllergyLymphoma

Narrower (3)

DepoCytDepoCyteDepoFoam

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma
Standard intrathecal chemotherapy for lymphomatous meningitis (LM) is limited by the short cerebrospinal half‐lives of the agents… 
2009
2009
Neoplastic meningitis from breast carcinoma with complete response to liposomal cytarabine: case report
Neoplastic meningitis from breast cancer often leads to a progressive neurologic deterioration followed by fatal outcome. The… 
2008
2008
Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: Experience of two pediatric institutions
The treatment of meningeal relapse in acute lymphoblastic leukemia (ALL) remains a challenging clinical problem. Liposomal… 
Review
2007
Review
2007
Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma
Patients with acute lymphocytic leukemia (ALL) and high-grade lymphoma have a 10 – 20% risk of meningeal disease during induction… 
2006
2006
Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases.
The depot formulation of liposomal cytarabine (DepoCyte) has proven to be useful as intrathecal (IT) treatment of neoplastic and… 
2002
2002
Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon α-2b for the treatment of chronic myelogenous leukemia patients in chronic phase
Cytarabine ocfosfate (YNK01) is a prodrug analogue of cytarabine which is resistant to systemic deamination after oral… 
1999
1999
Intraventricular concentration times time (C × T) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma
Intraventricular chemotherapy results in more uniform drug distribution within the subarachnoid space and allows for more… 
Highly Cited
1993
Highly Cited
1993
Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Children with acute lymphoblastic leukemia (ALL) who have completed 2.5 to 3 years of initial chemotherapy have an off-therapy… 
1989
1989
Reduced toxicity of intravitreally injected liposome-encapsulated cytarabine.
Cytarabine has been demonstrated to be a more potent inhibitor of fibroblast proliferation than fluorouracil. It is, however… 
1969
1969
Immunosuppressive effects of adamantoyl cytarabine. I. Inhibition of hemagglutinin formation and graft versus host reactions in mice.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)